International Journal of Pharmacy
Journal Homepage: http://www.pharmascholars.com

Short Communication **CODEN: IJPNL6**

Advancements in Antiviral and Immunomodulatory: Progress in Dengue Therapy

Karl Walter*

Department of Pharmacy, University of Durban, Durban, South Africa

***Corresponding author email**: Walterkarloson12@hotmail.com

Received: *16-Feb-2024, Manuscript No. IJP-24-130551;* ***Editor assigned:*** *20-Feb-2024, PreQC No. IJP-24-130551 (PQ);* ***Reviewed:*** *06-Mar-2024, QC No. IJP-24-130551;* ***Revised:*** *14-Mar-2024, Manuscript No. IJP-24-130551 (R);* ***Published:*** *21-Mar-2024, DOI:10.37532/2249-1848.2024.14(2).103*

ABOUT THE STUDY

Dengue fever, a mosquito-borne viral infection, poses a significant public health threat in tropical and subtropical regions worldwide. With no specific antiviral treatments available, the management of dengue primarily involves supportive care [1]. However, the emergence of novel therapeutic approaches offers promising avenues for combating this disease. In recent years, researchers have made significant strides in developing innovative therapies targeting various stages of the dengue virus lifecycle, from viral entry to replication and immune modulation [2].

Monoclonal antibodies

Monoclonal Antibodies (mAbs) have garnered attention as a potential therapeutic strategy for dengue fever. These antibodies are designed to target specific components of the dengue virus, such as envelope proteins or non-structural proteins, inhibiting viral replication and dissemination [3]. Several mAbs have shown promise in preclinical studies and early-stage clinical trials. For instance, the antibody 33D6 has demonstrated neutralizing activity against multiple dengue virus serotypes, highlighting its potential as a broad-spectrum therapeutic agent. Additionally, mAb-based therapies offer the advantage of passive immunization, providing immediate protection to individuals at risk of severe dengue [4].

Antiviral drug

Efforts to develop direct-acting antiviral drugs for dengue have intensified in recent years. These drugs target essential viral enzymes involved in replication, such as the RNA-dependent RNA polymerase and viral proteases [5]. One promising class of antiviral agents is nucleoside analogs, which interfere with viral RNA synthesis. Compounds like balapiravir have shown efficacy in inhibiting dengue virus replication in preclinical models and early-phase clinical trials. Furthermore, the development of combination therapies, incorporating multiple antiviral agents with complementary mechanisms of action, holds potential for enhancing efficacy and reducing the risk of viral resistance, encouraging an environment where patients feel comfortable reporting any unusual symptoms or concerns related to their medications [6].

Host-targeted therapies

Host-targeted therapies aim to modulate host factors essential for viral replication or immune response, offering a broader spectrum of antiviral activity. For instance, inhibitors of host cell kinases, such as p38 MAPK inhibitors, have been explored for their ability to suppress dengue virus replication by disrupting cellular processes necessary for viral propagation [7,8]. Similarly, immunomodulatory agents that mitigate excessive inflammation, such as corticosteroids or anti-inflammatory cytokines, may attenuate the cytokine storm associated with severe dengue, thereby improving clinical outcomes. However, the efficacy and safety of host-targeted therapies warrant further investigation to optimize treatment regimens and minimize adverse effects.

RNA interference (RNAi)

RNA interference (RNAi) represents a promising approach for inhibiting dengue virus replication by silencing viral RNA transcripts. Small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs) can be designed to target conserved regions of the dengue genome, preventing viral protein synthesis and assembly [9]. Several preclinical studies have demonstrated the efficacy of RNAi-based therapies in reducing viral load and mitigating disease severity in animal models of dengue infection. Moreover, the development of nanoparticle delivery systems enables the efficient delivery of RNAi molecules to target cells, overcoming barriers such as degradation and off-target effects [10].

Vaccine development

While not a conventional therapy for established dengue infections, vaccination plays a crucial role in disease prevention and control. The development of effective dengue vaccines has been a long-standing challenge due to the complexity of the virus and the risk of vaccine-induced enhancement of disease severity [11,12]. However,

recent advancements in vaccine technology have led to the licensure of several dengue vaccines, including CYD-TDV (Dengvaxia) and TAK-003 (Dengvaxia) [13,14]. These vaccines offer protection against multiple dengue virus serotypes and have demonstrated efficacy in reducing the incidence of severe dengue in vaccinated individuals. Ongoing research focuses on improving vaccine safety, efficacy, and accessibility to address the unmet needs of dengue-endemic populations [15].

CONCLUSION

The landscape of dengue therapy is evolving rapidly, driven by advancements in our understanding of the virus and the development of innovative treatment modalities. From monoclonal antibodies to host-targeted therapies and RNA interference, a diverse array of therapeutic approaches is being explored to combat dengue fever. While challenges remain, including the need for further clinical validation and optimization of treatment regimens, the progress made in recent years offers hope for the effective management and control of this debilitating disease. Continued investment in research and development efforts is essential to translate these promising therapies into tangible solutions for dengue-endemic regions globally. .

REFERENCES

1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. *Nature* 2013;496:504-507.
2. Vannice KS, Durbin A, Hombach J. Status of vaccine research and development of vaccines for dengue. *Vaccine*. 2016;34:2934-2938.
3. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. *N Engl J Med.* 2015;373:1195-206.
4. Villar L, Dayan GH, Arredondo-Garcia JL, et al Efficacy of a tetravalent dengue vaccine in children in Latin America. *N Engl J Med*. 2015;372:113-123.
5. Halstead SB, Russell PK. Protective and immunological behavior of chimeric yellow fever dengue vaccine. *Vaccine*. 2016;34:1643-1647.
6. World Health Organization. Global strategy for dengue prevention and control, 2012-2020. Geneva, Switzerland: *WHO Press*. 2012.
7. Lescar J, Luo D, Xu T, et al. Towards the design of antiviral inhiitors against flaviviruses: The case for the multifunctional NS3 protein from Dengue virus as a target. *Antiviral Res.* 2008;80:94-101.
8. Chan YK, Gack MU. Viral evasion of intracellular DNA and RNA sensing. *Nat Rev Microbiol.* 2016;14:351-373.
9. Wang QY, Patel SJ, Vangrevelinghe E, et al. A small-molecule dengu virus entry inhibitor. *Antimicrob Agents Chemother*. 2009;53:1823-1831.
10. Robinson LN, Tharakaraman K, Rowley KJ. et al. Structure-guided design of an anti-dengue antibody directed to a non-immunodominant epitope. *Cell*. 2015;162:493-504.
11. Teoh EP, Kukkaro P, Teo EW, et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. *Sci Transl Med*. 2012;4:139ra83.
12. Luo D, Vasudevan SG, Lescar J. The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development. *Antiviral Res.* 2015;118:148-158.
13. Sung C, Kumar GS, Vasudevan SG. Dengue drug development. dengue and dengue hemorrhagic fever. 2nd edition. UK: *CABI*. 2014.
14. Byrd CM, Dai D, Grosenbach DW et al A novel inhibitor of dengue virus replication that targets the capsid protein. *Antimicrob Agents Chemother*. 2013;57:15-25.
15. Becker GL, Lu Y, Hardes K, et al. Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. *J Biol Chem*. 2012;287:21992-22003.